Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study
2018
Аутори
Jovanović, DraganaMilenković, Marina
Kotur-Stevuljević, Jelena
Marković, Jelena
Ceriman, Vesna
Kontić, Milica
Skodrić-Trifunović, Vesna
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background: Idiopathic pulmonary fibrosis (IPF) has common risk factors with cancer and significant similarities in the pathobiology process, both diseases having poor outcomes. Immune checkpoint PD-L1 has become the target of checkpoint inhibitory therapy that unleashes antitumor T cells and has revolutionized cancer treatment. This is a pilot study exploring membrane immune checkpoint PD-L1 expression in human IPF lung tissue samples and its soluble form, soluble PD-L1 (sPD-L1) plasma concentrations in IPF patients, in order to investigate potential role of PD-L1 as an IPF biomarker. Methods: Twelve human IPF lung tissue samples (formalin-fixed, paraffin-embedded) obtained by surgical biopsy, have been tested for PD-L1 expression by PD-L1 IHC 22C3 pharmDx assay, while plasma samples for examination of sPD-L1 forms, PD-L1 (B7-H1/CD274) blood concentration, originated from 23 patients with IPE who did not undergo surgical biopsy. Results: Membrane PD-L1 expression in IPF lung tissue sa...mples was positive to overexpression of PD-L1 in 9 samples out of 12. Only very few cells in the interstitium have shown a discrete PD-L1 expression, but not of a membrane type. As for sPD-L1 forms, we have found elevated concentrations of sPD-L1 in the serum of IPF patients 314.3 ng/L (117.7-483.1 ng/L), significantly higher compared with healthy control group 91.0 ng/L (52.4-119.7 ng/L), P lt 0.01. Conclusions: For IPF with PD-L1 expression on alveolar macrophages, further studies are necessary to elucidate this phenomenon. Serum sPD-1/PD-L1 is easily detected in clinical practice and should be further evaluated as a potential prognostic or/and predictive biomarker in IPF.
Кључне речи:
Idiopathic pulmonary fibrosis (IPF) / membrane PD-L1 expression / soluble PD-L1Извор:
Journal of Thoracic Disease, 2018, 10, 12, 6660-6669Издавач:
- Ame Publ Co, Shatin
Финансирање / пројекти:
- Клиничко епидемиолошка истраживања најчешћих нежељених догађаја током болничког лечења (RS-MESTD-Basic Research (BR or ON)-175046)
DOI: 10.21037/jtd.2018.11.16
ISSN: 2072-1439
PubMed: 30746211
WoS: 000456834700070
Scopus: 2-s2.0-85059540040
Институција/група
PharmacyTY - JOUR AU - Jovanović, Dragana AU - Milenković, Marina AU - Kotur-Stevuljević, Jelena AU - Marković, Jelena AU - Ceriman, Vesna AU - Kontić, Milica AU - Skodrić-Trifunović, Vesna PY - 2018 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3136 AB - Background: Idiopathic pulmonary fibrosis (IPF) has common risk factors with cancer and significant similarities in the pathobiology process, both diseases having poor outcomes. Immune checkpoint PD-L1 has become the target of checkpoint inhibitory therapy that unleashes antitumor T cells and has revolutionized cancer treatment. This is a pilot study exploring membrane immune checkpoint PD-L1 expression in human IPF lung tissue samples and its soluble form, soluble PD-L1 (sPD-L1) plasma concentrations in IPF patients, in order to investigate potential role of PD-L1 as an IPF biomarker. Methods: Twelve human IPF lung tissue samples (formalin-fixed, paraffin-embedded) obtained by surgical biopsy, have been tested for PD-L1 expression by PD-L1 IHC 22C3 pharmDx assay, while plasma samples for examination of sPD-L1 forms, PD-L1 (B7-H1/CD274) blood concentration, originated from 23 patients with IPE who did not undergo surgical biopsy. Results: Membrane PD-L1 expression in IPF lung tissue samples was positive to overexpression of PD-L1 in 9 samples out of 12. Only very few cells in the interstitium have shown a discrete PD-L1 expression, but not of a membrane type. As for sPD-L1 forms, we have found elevated concentrations of sPD-L1 in the serum of IPF patients 314.3 ng/L (117.7-483.1 ng/L), significantly higher compared with healthy control group 91.0 ng/L (52.4-119.7 ng/L), P lt 0.01. Conclusions: For IPF with PD-L1 expression on alveolar macrophages, further studies are necessary to elucidate this phenomenon. Serum sPD-1/PD-L1 is easily detected in clinical practice and should be further evaluated as a potential prognostic or/and predictive biomarker in IPF. PB - Ame Publ Co, Shatin T2 - Journal of Thoracic Disease T1 - Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study VL - 10 IS - 12 SP - 6660 EP - 6669 DO - 10.21037/jtd.2018.11.16 ER -
@article{ author = "Jovanović, Dragana and Milenković, Marina and Kotur-Stevuljević, Jelena and Marković, Jelena and Ceriman, Vesna and Kontić, Milica and Skodrić-Trifunović, Vesna", year = "2018", abstract = "Background: Idiopathic pulmonary fibrosis (IPF) has common risk factors with cancer and significant similarities in the pathobiology process, both diseases having poor outcomes. Immune checkpoint PD-L1 has become the target of checkpoint inhibitory therapy that unleashes antitumor T cells and has revolutionized cancer treatment. This is a pilot study exploring membrane immune checkpoint PD-L1 expression in human IPF lung tissue samples and its soluble form, soluble PD-L1 (sPD-L1) plasma concentrations in IPF patients, in order to investigate potential role of PD-L1 as an IPF biomarker. Methods: Twelve human IPF lung tissue samples (formalin-fixed, paraffin-embedded) obtained by surgical biopsy, have been tested for PD-L1 expression by PD-L1 IHC 22C3 pharmDx assay, while plasma samples for examination of sPD-L1 forms, PD-L1 (B7-H1/CD274) blood concentration, originated from 23 patients with IPE who did not undergo surgical biopsy. Results: Membrane PD-L1 expression in IPF lung tissue samples was positive to overexpression of PD-L1 in 9 samples out of 12. Only very few cells in the interstitium have shown a discrete PD-L1 expression, but not of a membrane type. As for sPD-L1 forms, we have found elevated concentrations of sPD-L1 in the serum of IPF patients 314.3 ng/L (117.7-483.1 ng/L), significantly higher compared with healthy control group 91.0 ng/L (52.4-119.7 ng/L), P lt 0.01. Conclusions: For IPF with PD-L1 expression on alveolar macrophages, further studies are necessary to elucidate this phenomenon. Serum sPD-1/PD-L1 is easily detected in clinical practice and should be further evaluated as a potential prognostic or/and predictive biomarker in IPF.", publisher = "Ame Publ Co, Shatin", journal = "Journal of Thoracic Disease", title = "Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study", volume = "10", number = "12", pages = "6660-6669", doi = "10.21037/jtd.2018.11.16" }
Jovanović, D., Milenković, M., Kotur-Stevuljević, J., Marković, J., Ceriman, V., Kontić, M.,& Skodrić-Trifunović, V.. (2018). Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. in Journal of Thoracic Disease Ame Publ Co, Shatin., 10(12), 6660-6669. https://doi.org/10.21037/jtd.2018.11.16
Jovanović D, Milenković M, Kotur-Stevuljević J, Marković J, Ceriman V, Kontić M, Skodrić-Trifunović V. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. in Journal of Thoracic Disease. 2018;10(12):6660-6669. doi:10.21037/jtd.2018.11.16 .
Jovanović, Dragana, Milenković, Marina, Kotur-Stevuljević, Jelena, Marković, Jelena, Ceriman, Vesna, Kontić, Milica, Skodrić-Trifunović, Vesna, "Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study" in Journal of Thoracic Disease, 10, no. 12 (2018):6660-6669, https://doi.org/10.21037/jtd.2018.11.16 . .